Samsung Medison, a global medical equipment company and an affiliate of Samsung Electronics, has signed an agreement to acquire 100% of the shares of Sonio SAS, a fetal ultrasound AI software company.
Established in 2020 to enhance women’s and children’s health globally through medical advancements, Sonio has developed IT solutions and AI assistant features for obstetrics and gynaecology ultrasound that assist medical professionals in evaluating and documenting ultrasound exams.
Sonio Detect, an FDA 510(k) cleared AI assistant, leverages deep learning networks to ensure higher image quality in real-time and improve the quality of care through greater clinical accuracy.
Following the completion of the transaction, Sonio will remain an independent company headquartered in France. It will continue its commercial growth independently, and its products and services will remain compatible with all ultrasound device makers.
Together with Sonio’s world-class AI expertise, Samsung Medison’s leading-edge ultrasound systems will help bring to market breakthrough AI-enhanced workflows and accelerate innovation in patient outcomes and quality of prenatal care.
“We have great respect and admiration for what the Sonio team has built in maternal care. Through the acquisition of Sonio, Samsung Medison will continue to deliver upon our promise to improve the quality of people’s lives with technology,” said Yong Kwan Kim, Samsung Medison CEO. “Collaboration with Sonio will bring together best-in-class ultrasound AI technology and reporting capabilities to bring a paradigm shift in the prenatal ultrasound exam.”
“Samsung Medison’s established global ultrasound business combined with Sonio’s advanced AI creates an exciting growth opportunity for both sides,” said Cécile Brosset, Sonio CEO. “We have found in Samsung Medison an amazing, trusting partner to pursue and accelerate our roadmap and mission. In addition to close collaboration with Samsung Medison, as an independent company, Sonio will continue to advance medical reporting technology and diagnostic software globally, including for underserved areas in healthcare.”
The closing of the transaction is subject to applicable regulatory approvals, and notably the approval of the French Ministry of the Economy and Finance.
